All News

AI.think_.brain_.jpg

AI Passes U.S. Medical Licensing Exam

d MedPage Today

Two artificial intelligence (AI) programs -- including ChatGPT -- have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers.

Read Article
rare

VEXAS may be more common than expected

d Jack Cush, MD

A great study of a recently described rheumatologic/hematologic disorder VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant. 

Read Article
OA,biomarker

Blood Test Identifies Osteoarthritis Progression

d EurekAlert!

A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.

Read Article
pregnant.baby_.hands_.jpg

Variable Pregnancy Outcomes with Belimumab in SLE

d Jack Cush, MD

An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to

Read Article
knee.surg2_.jpg (keep)

Periprosthetic Joint Infections

d Jack Cush, MD

Recent NEJM has reviewed arthroplasty-associated infection and periprosthetic joint infections (PJI), noting this is a rare event; notably these infections are caused by skin microorganisms introduced during arthroplasty surgery or may be seeded post-surgically, via hematogenously spread or compromised local tissues (skin or bone).

Read Article
JAK Janus

JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?

d Jack Cush, MD

Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).

Read Article
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx

Links:

Dr. John Cush RheumNow ( View Tweet)
Why not end your patient visit with a recitation pledging your service and commitment: "Your coming to see me to day is very important, to the both of us. I pledge to be of service to you. Together WE can certainly improve your health" https://t.co/9U95LoiDQi https://t.co/dMWunEXjWk

Links:

Dr. John Cush RheumNow ( View Tweet)
Recent NEJM has reviewed arthroplasty-associated infection and PJI, noting this is a rare event; notably these infections are caused by skin microorganisms introduced during arthroplasty surgery or may be seeded post-surgically. https://t.co/DXflkGnsdK https://t.co/GgfeSSl4xJ

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure? Data from 17 international registries suggest that for RA patients failing their first JAKi, it did not matter if they were cycled to another JAKi or switched to a bDMARD. https://t.co/xLZveIoaRG https://t.co/tBpJUgOqaN

Links:

Dr. John Cush RheumNow ( View Tweet)
Burden of BMI on Costs of Musculoskeletal Diseases A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders. https://t.co/EZJTnLeaOZ https://t.co/sAOQ3fuq8Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Subanalysis of Scleroderma Lung Study II (MMP vs CTX in SSc-ILD) showed pt reported GI reflux (~moderate) was independently associated with the change ILD and fibrosis over two years (but not so for esophageal dilation) https://t.co/6wRCM0PW2a https://t.co/uc2dfdnlhu

Links:

Dr. John Cush RheumNow ( View Tweet)
Free read review of IL-15 - crucial for the homeostasis of NK & memory CD8 T cells; IL-15 dysregulations are important autoimmune Dz & hematological malignancies. How to target the actions of IL-15 are discussed https://t.co/yUuUIOCAC6 https://t.co/nLnC37GdMS

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA oversees US drug sales, the largest single market for pharmaceuticals globally, worth an estimated $528 billion in 2020 in public and private spending (Figure 1). https://t.co/DMwoYIIyHP https://t.co/9nGStaotrO

Links:

Dr. John Cush RheumNow ( View Tweet)
Inpatient health care utilization studied in 341 #SLE pts vs 341 non-SLE. SLE had more hospitalizations (30 vs 10/100PY) and more ED visit (HR 2.71) and Hospital readmission rates (32% vs. 21%, p = 0.017) https://t.co/vsW7Ol9b4O https://t.co/hpmcFuF8Pm

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean study of 439 RA pts starting JAKi, TNFi or non-TNFi. Physician choice of JAKi was more likely with age (OR 1.03), no pulmonary Dz (OR 0.07), Higher Dz activity (OR 1.80) & prior tacrolimus (OR 2.05) https://t.co/9Vv5XfzfrH https://t.co/59Whi7tCIE

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA: 13 million In US have latent TB (5-10% risk of getting active TB). Review of LTBI regimens: - Preferred: 4 mos Rifampin: better/safer of INH - Preferred: 3 mos of INH + rifapentine - more completers less SAE - ALternative: 6-9 mos of INH https://t.co/vZTmSKTFWu https://t.co/W7BraJs6yC

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Til Death Do Us Part Dr. Jack Cush reviews the highlights from the past week on RheumNow https://t.co/nSogWCSbi9 https://t.co/nZ9jWu20Xy

Links:

Dr. John Cush RheumNow ( View Tweet)
AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality. https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×